Pharmacokinetics and tolerability of single-dose daptomycin in young infants

Pediatric Infectious Disease Journal

Volumn 31, Issue 9, 2012, Pages 935-937

  Cohen Wolkowiez, Michael ^a,b   Watt, Kevin M ^a,b   Hornik, Christoph P ^a,b   Benjamin, Daniel K ^a,b   Smith, P Brian ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

complicated skin and skin structure infections; daptomycin; pharmacokinetics; Staphylococcus aureus

Indexed keywords

AMPICILLIN; CAFFEINE; DAPTOMYCIN; GENTAMICIN;

ADOLESCENCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BIRTH; CLINICAL ARTICLE; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DIAPHRAGM HERNIA; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; GESTATIONAL AGE; HUMAN; INFANCY; INFANT; MALE; PHARMACOKINETICS; PLASMA; PNEUMATOCELE; PRIORITY JOURNAL; RADIOGRAPHY; SIDE EFFECT; SINGLE DRUG DOSE; STAPHYLOCOCCUS INFECTION; THORAX DISEASE;

ANTI-BACTERIAL AGENTS; BACTEREMIA; DAPTOMYCIN; FEMALE; HUMANS; INFANT, NEWBORN; MALE; PROSPECTIVE STUDIES; STAPHYLOCOCCAL SKIN INFECTIONS;

EID: 84865468070     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31825d2fa2     Document Type: Article

References (15)

1. Daptomycin (Cubicin®) Package Literature. Lexington, MA: Cubist Pharmaceuticals, Inc.; 2003.
2. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110(2 Pt 1):285-291.
3. Oudin C, Vialet R, Boulamery A, et al. Vancomycin prescription in neonates and young infants: toward a simplified dosage. Arch Dis Child Fetal Neonatal Ed. 2011;96:F365-F370.
4. Cohen-Wolkowiez M, Smith PB, Benjamin DK Jr, et al. Daptomycin use in infants: report of two cases with peak and trough drug concentrations. J Perinatol. 2008;28:233-234.
5. Abdel-Rahman SM, Benziger DP, Jacobs RF, et al. Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. Pediatr Infect Dis J. 2008;27:330-334.
6. Dvorchik B, Damphousse D. Single-dose pharmacokinetics of daptomycin in young and geriatric volunteers. J Clin Pharmacol. 2004;44:612-620.
7. Dvorchik BH, Brazier D, DeBruin MF, et al. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 2003;47:1318-1323.
8. Dvorchik B, Arbeit RD, Chung J, et al. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2004;48:2799-2807.
9. Dvorchik B. Moderate liver impairment has no influence on daptomycin pharmacokinetics. J Clin Pharmacol. 2004;44:715-722.
10. Oleson FB, Berman CL, Li AP. An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes. Chem Biol Interact. 2004;150:137-147.
11. Singh J, Burr B, Stringham D, et al. Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics. Paediatr Drugs. 2001;3:733-761.
12. Abdel-Rahman SM, Chandorkar G, Akins RL, et al. Single-dose pharmacokinetics and tolerability of daptomycin 8 to 10 mg/kg in children aged 2 to 6 years with suspected or proved Gram-positive infections. Pediatr Infect Dis J. 2011;30:712-714.
13. Sarafidis K, Iosifidis E, Gikas E, et al. Daptomycin use in a neonate: serum level monitoring and outcome. Am J Perinatol. 2010;27:421-424.
14. Arbeit RD, Maki D, Tally FP, et al.; Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673-1681.
15. Food and Drug Administration. Cubicin® (daptomycin for injection) for the treatment of Staphylococcus aureus bacteremia, including those with known or suspected infective endocarditis: FDA Briefing Document for Anti-Infective Drugs Advisory Committee Meeting, March 6, 2006. Rockville, MD: Food and Drug Administration 2006.